Articles On Neurotech International (ASX:NTI)

Integral Diagnostics and Medadvisor have new CEOs after the latest round of changes at the top Mayne’s refrain: let the Takeovers Panel decide It’s a case of the MEGnificent Five as Compumedics sells another brain-scanning device in China...

In this latest episode of Stockhead’s Who’s Who on the ASX, host Tylah Tully spotlights Neurotech (ASX:NTI), a clinical-stage biopharmaceutical company developing innovative cannabinoid-based therapies for paediatric neurological disorders....

ASX down 9 points as AI jitters and profit taking set in Healthcare, materials sectors limit losses with some solid gains PainChek and Neurotech grab headlines with FDA wins; Dimerix also gains on strong news Glencore Mt Isa smelter bailed...

PainChek can now tackle the US$100 million US aged-care market – while other geographies beckon Trivarx shares leap 9% on depression detection trial results Dimerix gets more assurances on using surrogate endpoints in its pivotal kidney t...

US FDA grants Rare Paediatric Disease Designation for Neurotech’s NTI164 for treatment of Rett syndrome Designation helps facilitate innovative treatments for rare paediatric diseases with enhanced regulatory support and potential priorit...

Host Tylah Tully speaks with Neurotech International (ASX:NTI) CEO Anthony Filippis about the company’s recent progress with its lead drug candidate NTI164, a unique cannabinoid therapy targeting paediatric neurological disorders such as au...

ASX rises 0.4pc with eight of 11 sectors higher Materials, major banks lead gains Myer takes an absolute beating Gold bull run continues Everyone’s favourite precious metal is continuing its bull run and dragging the ASX with it. Gold fut...

Neurotech starts an authorised prescriber program for NTI164 in neurodevelopmental conditions The program provides controlled, specialist-led access for eligible patients in Australia, addressing strong patient and family demand It will ge...

Australia’s S&P/ASX 200 rose 3.10% in August and has posted gains of 12.33% so far for CY25 Materials led the gainers up 9.19%, while Healthcare fell 13.21% with CSL having its biggest ever daily fall Rare earths explorer Kaili Resourc...

Rett syndrome is rare but relentless Neuren struck biotech gold with Daybue Neurotech brings cannabis to the fight   Rett syndrome is the kind of diagnosis that hits hard and lingers long. It affects around one in 10,000 girls, and typica...

Neurotech (ASX:NTI) chief medical advisor USA Dr. Bonni Goldstein joins host Tylah Tully to discuss the promising future of the company’s NTI164, a cannabinoid-based therapy for children with neurological disorders like autism, Rett syndrom...

What are ASD and Rett syndrome? How do they affect children and families? Why is there a need for new treatment options in neurodevelopmental care? And what excites Professor Fahey most about NTI164’s future? In this interview, Professor Mi...

MND strips voice and movement from thousands Big Freeze and Neale Daniher lead the national fight Control Bionics tech gives the silent a voice   There’s a reason it’s called the Beast. Motor Neurone Disease (MND) creeps in quietly and sl...

The S&P/ASX 200 Health Care Index rose 1.59% in May but remains worst performing sector YTD down 5.65% Morgans healthcare analyst Iain Wilkie said US President Donald Trump’s trade and health policies continue to impact sector Lumos up...

Neurotech reports positive results from first-in-human pharmacokinetic study of broad-spectrum cannabinoid drug NTI164 Study confirms fast, predictable absorption of NTI164, with CBDA as main cannabinoid Minimal THC exposure confirms NTI16...

Australia has become well-known for its paediatric drug discovery with several life-altering treatments CSL is a global leader in developing therapies for children with haemophilia and other serious blood disorders Neurotech International...

Special Report: Neurotech has cleared a key safety hurdle for its lead drug NTI164, with new toxicology results paving the way for longer-term studies, and global regulatory submissions. Neurotech International (ASX: NTI) has delivered a ma...

Sandoz backs Avecho in $3m CBD sleep capsule play Neurotech also eyes sleep as secondary endpoint in CBD trials The hot sleep space is led by companies like Resmed and Compumedics   Melbourne-based biotech Avecho has just pulled off a big...

There are several ASX biotech companies developing drugs to treat complex neurological conditions Global neurological disorder drugs market size set to reach US$149.17 billion by 2032 Petra Capital’s Tanushree Jain says neurological disord...

ASX drops on tariff fears; BHP, Rio hit Star Entertainment Group sinks amid financial crisis Life360 shines as Endeavour tanks   It was a rough day for the ASX, dropping 1.16% as fears over new US-China tariffs sent Aussie stocks spiralli...

From artificial intelligence (A.I) to zygotes, the biotech sector this year delivered the A to Z of excitement, intrigue, occasional disappointment and downright disaster. His virtual stethoscope on hand, Dr Boreham was on duty to diagnose...

Today, our biotech Investment, Neurotech International (ASX: NTI) announced it has received US FDA Orphan Drug Designation for its treatment for Rett Syndrome.

WA biotech Neurotech International has won vital ethics approval for its cannabinoid drug therapy aimed at treating neurological disorders in children.

The ASX200 has been up 0.7% after hitting a new all time intra-day high of 8,462 points. The bourse continues to trade close to record levels and analyst chatter is swirling around whether it will be a record close. The Real Estate secto...

Stockhead’s Break it Down brings you today’s leading market news in under 90 seconds. In this episode, host Sarah Hughan tells all on Neurotech’s (ASX:NTI) vital approval to start its human pharmacokinetic study in Adelaide. The company’s o...

Neurotech (ASX:NTI) has bounced back from a recent fast-track status rejection from the FDA, now launching a NTI164 baseline data study. On October 4, Neurotech flagged to the market the US regulator FDA had knocked back its application...

The ASX200 is set to open 0.44% higher today, despite weak performances on Wall Street after US Federal Reserve Chair Jerome Powell suggested rates would not be cut anytime soon. The S&P 500 and Nasdaq both fell 0.6% on Thursday, whi...

Neurotech appoints biotech veteran Dr Anthony Filippis as its managing director Filippis has deep understanding of industry and a strong track record of partnering success and capital markets expertise Experience will help company execute...

True to its history of reinvention and repurposing, Pharmaust will be renamed Neurizon Therapeutics after shareholders approved the moniker change at Wednesday’s AGM. The new name “combines our focus on neuro-degenerative diseases with the...

Mesoblast expects FDA stem cell drug approval by the first week of January ‘if not earlier’ FDA to Somnomed: ‘do you want the good news or bad news first?’ Neurotech mulls its US options after FDA’s orphan drug decision Orthocell says reve...

Highlights ASX200 falls 0.67%, led by declines in mining and IT sectors. Energy sector rises, driven by oil price surge amid Middle East tensions. Notable movements include gains in Strike Energy and declines in Neurotech Internationa...

The ASX200 has closed 0.67% lower at 8,150 points. Investors have rising concerns about the Middle Eastern conflict and are responding by exiting equities perceived to pose risk. To the sectors, Energy was the strongest performer, up...

A WA listed biotech has failed in its bid to get major backing from the US Food and Drug Administration for its cannabinoid drug therapy aimed at treating neurological disorders in children.

Neurotech International (NTI) has flagged to its shareholders that the FDA hasn’t granted its product NTI164 orphan drug status. Orphan drug status is that classification awarded to drugs by the FDA for, often, rare diseases. Companies...

Australia’s clinical trials sector generated $1.6bn for the nation’s economy in 2022 according to MTPConnect PharmAust is currently undertaking a Phase 1 open label extension study at two sites in Australia Dimerix has seven Australian sit...

MTPConnect said Australia has a global reputation as a ‘go to’ destination to conduct clinical trials Sector generated $1.6bn for the Australia economy in 2022, up by more than 4% on 2019 figures Argenica said cost to conduct trials in Aus...

  ASX slips  as US jobs data fuels Wall Street panic Westpac gets a new CEO Newcomers into the ASX200 index include Guzman u Gomez   The ASX stumbled by 0.3% on Monday after the US jobs report fell short on Friday night, causing Wall Str...

  Neurotech reports positive genomic analysis of NTI164 as part of Phase 1/2 PANDAS/PANS trial NTI164 shown to positively modify immune cell function and address gene translation dysregulation Disease-modifying potential of NTI164 may impr...

  Adelong Gold (ASX:ADG) has engaged a new exploration consultant to advance the Adelong Gold Project. Initial soil sampling has revealed promising indications of arsenic and antimony, suggesting potential gold mineralisation. A drilling pr...

ASX 200 up on Friday boosted by strong US GDP and Wall Street gains Star Entertainment gets scathing remarks from regulator Downer EDI and TPG Telecom among the stocks to surge today   The ASX closed 0.58% higher on Friday as investors di...

Over the last few years Neurotech International (ASX: NTI) has been gathering a significant amount of clinical evidence that its product NTI164 is effective in treating multiple neurological disorders in children.

ASX rises circa 0.5pc Consumer stocks in focus this week SGQ and PHX lead small caps   Aussie stocks have closed higher on Monday as IT and retail stocks added strength to sentiment. The S&P/ASX200 closed higher, gaining 36.00 points...

Neurotech to secure one or more strategic partnerships for NTI164 in the US, Europe and Asia Partnerships aim to support clinical, regulatory development, manufacturing and future market launches of NTI164 Neurotech to pursue multiple regi...

Tryptamine’s psilocybin trial indicates potential for treating fibromyalgia Actinogen says Xanamem eases depression but misses cognitive goals PYC reports vision gains using experimental eye drug   Tryptamine’s Phase 2a trial shows promis...

ASX rises on Wednesday after soft June Qtr CPI bump All sectors end higher Small caps led by GTE and SPA   The local benchmark index is back in record territory after extended gains on Wednesday as quarterly inflation data assuaged fea...

  Neurotech reports positive results from extension phase of Phase 1/2 trial of NTI164 to treat Rett Syndrome NTI164 is first broad-spectrum cannabinoid drug therapy to show significant clinical improvement in Rett Syndrome patients All 14...

The cannabis industry is poised for growth, driven by evolving legalisation globally Investment opportunities therefore exist across the sector We take a look at the ASX weed stock winners over the past month    The cannabis industry is c...

There are currently no approved treatments available to help children with Autism Spectrum Disorder (ASD). Our biotech Investment Neurotech International (ASX: NTI) is looking to change this.

ASX 200 closes 0.16pc lower after modest rally from morning lows  Six of 11 sectors lower, after rate-sensitive sectors improve after lunch  Killi Resources surges again with a late surge to dethrone Infini   Local markets have trimmed...

Neurotech reports further benefits from Phase 2/3 trial of NTI164 in autism patients Patients showed 56% improvement in CGI-S score from baseline at week 12 Patients unblinded at end of week eight showed 21% improvement in CGI-S score to w...